Inorganic phosphate (Pi) (Pi)

Inorganic phosphate in the gastrointestinal lumen is a critical pharmacological target for managing mineral and bone disorders, particularly in patients with chronic kidney disease (CKD) (StatPearls, 2023). Phosphate is primarily obtained through diet and absorbed in the small intestine via both passive paracellular and active transcellular pathways (PubMed, 2021). In patients with impaired renal function, the inability to excrete excess phosphate leads to hyperphosphatemia, which is associated with secondary hyperparathyroidism, vascular calcification, and increased cardiovascular mortality (NIH, 2022). Therapeutic intervention involves the use of phosphate binders, which are orally administered agents that chemically react with or adsorb inorganic phosphate within the gut lumen (PubChem, 2024). By forming insoluble complexes that are excreted in the feces, these drugs effectively reduce the amount of phosphate available for absorption into the systemic circulation (Journal of Nephrology, 2020). This mechanism is distinct from systemic drugs as it acts locally within the digestive tract to lower the total body burden of phosphorus. Common binders include calcium-based salts, polymer-based resins like sevelamer, and metal-based compounds like lanthanum carbonate or iron-based oxyhydroxides. Effective management of luminal phosphate is essential for preventing the progression of CKD-Mineral and Bone Disorder (CKD-MBD).

Other names

Dietary phosphateIntestinal phosphateOrthophosphatePhosphorus

Phosphate binders act by binding to inorganic phosphate in the gastrointestinal tract to form insoluble complexes, which prevents its absorption into the systemic circulation and promotes its excretion in the feces.